Sanofi and Regeneron acknowledged that testing their inflammatory disease blockbuster Dupixent in chronic obstructive pulmonary disease (COPD) was likely to be high-risk when they launched phase 3 ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

The drug is taken by more than a million patients around the world, Regeneron Chief Executive Leonard Schleifer told analysts on the company's earnings call. "Regarding the ongoing launch in COPD ...

The fact that the US Food and Drug Administration has approved using Dupixent to treat COPD positions Regeneron to generate billions of dollars in annual sales. Dupixent has the potential to ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on Regeneron (REGN – Research ... for chronic obstructive pulmonary disease (COPD) has garnered significant coverage from top ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...